BCG048
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
BCG048, a novel bispecific dual-payload ADC targeting ITGB6 and B7H3, exhibited potent efficacy in patient-derived tumor xenograft models
(AACR 2026)
- "Abstract is embargoed at this time."
ADC • Bispecific • Late-breaking abstract • Preclinical • Oncology • CD276 • ITGB6
1 to 1
Of
1
Go to page
1